Eagle Pharmaceuticals Inc. (EGRX) Trading 3.8% Higher
Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)’s share price traded up 3.8% during mid-day trading on Tuesday . The company traded as high as $63.48 and last traded at $62.21, with a volume of 855,930 shares. The stock had previously closed at $59.91.
A number of equities research analysts have recently commented on the stock. Mizuho downgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $66.00 to $47.00 in a report on Monday, June 20th. TheStreet upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Royal Bank Of Canada lowered their price target on shares of Eagle Pharmaceuticals from $94.00 to $78.00 and set an “outperform” rating for the company in a report on Tuesday, May 10th. Finally, Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $91.94.
The company has a market capitalization of $901.42 million and a PE ratio of 295.64. The stock’s 50 day moving average price is $50.58 and its 200-day moving average price is $47.72.
Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.09. During the same quarter in the prior year, the company earned ($0.53) EPS. The company earned $40.90 million during the quarter, compared to the consensus estimate of $43.55 million. The business’s quarterly revenue was up 581.7% on a year-over-year basis. Analysts anticipate that Eagle Pharmaceuticals Inc. will post $3.21 EPS for the current year.
In other Eagle Pharmaceuticals news, major shareholder Proquest Investments Iv, L.P. sold 24,949 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $60.77, for a total value of $1,516,150.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
An institutional investor recently raised its position in Eagle Pharmaceuticals stock. Schwab Charles Investment Management Inc. raised its position in shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) by 3.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,055 shares of the specialty pharmaceutical company’s stock after buying an additional 804 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.17% of Eagle Pharmaceuticals worth $2,399,000 as of its most recent filing with the SEC.
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.